DoD Tuberous Sclerosis Complex Exploration-Hypothesis Development Award

Funding Opportunity ID: 283645
Opportunity Number: W81XWH-16-TSCRP-EHDA
Opportunity Title: DoD Tuberous Sclerosis Complex Exploration-Hypothesis Development Award
Opportunity Category: Discretionary
Opportunity Category Explanation:
Funding Instrument Type: Cooperative Agreement
Category of Funding Activity: Science and Technology and other Research and Development
Category Explanation:
CFDA Number(s): 12.420
Eligible Applicants: Unrestricted (i.e., open to any type of entity above), subject to any clarification in text field entitled “Additional Information on Eligibility”
Additional Information on Eligibility:
Agency Code: DOD-AMRAA
Agency Name: Department of Defense
Dept. of the Army — USAMRAA
Posted Date: May 09, 2016
Close Date: Jul 18, 2016
Last Updated Date: May 09, 2016
Award Ceiling:
Award Floor:
Estimated Total Program Funding: $1,600,000
Expected Number of Awards: 5
Description: The EHDA supports the initial exploration of innovative, high-risk, high-gain, and potentially groundbreaking concepts in the TSC research field. The studies supported by this award mechanism are expected to lay the groundwork for future avenues of scientific investigation. The proposed research project should include a well-formulated, testable hypothesis based on strong scientific rationale and study design. Preliminary and/or published data are not required. The proposed research project must be innovative, feasible, and supported by strong rationale. Innovative research may introduce a novel paradigm, challenge existing paradigms, look at existing problems from novel perspectives, or exhibit other highly creative qualities. Research that is an incremental advance upon published data is not considered innovative and is not consistent with the intent of this award mechanism. It is the responsibility of the Principal Investigator (PI) to clearly and explicitly articulate how the proposed research project is innovative in the field of TSC. Research involving human subjects and human anatomical substances is permitted; however, studies must be exempt under Title 32 of the Code of Regulations, Part 219.101(b) (32 CFR 219.101(b)) or eligible for expedited review (32 CFR 219.110 or 21 CFR 56.110). Exemption or expedited status is first determined by the Institutional Review Board (IRB) of record. Investigators must review their institutional requirements and guidelines for filing with the IRB for exempt or expedited status. Studies that do not qualify for exempt or expedited status will be administratively withdrawn. Clinical trials are not allowed under this Program Announcement/Funding Opportunity. For more information on clinical trials and clinical research overall, a Human Subject Resource Document is provided on the electronic Biomedical Research Application Portal (eBRAP) system at PIs wishing to apply for funding for a pilot clinical trial should utilize the FY16 TSCRP Pilot Clinical Trial Award mechanism (Funding Opportunity Number: W81XWH-16-TSCRP-PCTA).
Version: Synopsis 1



Please enter your comment!
Please enter your name here